OVARIAN
CANCER
AWARENESS MONTH

1815

AUSTRALIANS WILL BE
DIAGNOSED WITH OVARIAN
CANCER THIS YEAR

49%

OF THOSE DIAGNOSED WITH
OVARIAN CANCER WILL
SURVIVE FIVE YEARS FROM
DIAGNOSIS

1016

AUSTRALIANS WILL LOSE THEIR
LIVES TO OVARIAN CANCER
THIS YEAR

Risk factors

- Age
- Endometriosis
- Infertility
- PCOS
- Smoking
- BRCA 1&2, Lynch Syndrome
- Protective #'s: Pregnancy, breastfeeding, hormonal contraception, tubal ligation or salpingectomy

Screening:

- Ca125
- Others? Ca 19.9, CEA, HE4
- Ultrasound (Solid, projections, vascular)

But why not??

- Poor sensitivity (50% of stage 1 do not have elevated Ca125)
- Poor specificity
- Low incidence, therefore low pre-test probability
- High NNT
- Risk

PLCO trial

- After 15 years of follow up, no benefit shown to ovarian cancer screening
- N = 40k each arm
- 187 vs 176 deaths intervention vs usual care (RR 0.87 – 1.30)
- No difference when stratified for risk factors
- No difference US, or Ca 125, or combination
- UKCTOKS trial, smaller, initial follow up promising, 16 year follow up = no difference
- Prevalence of +ve screening test result:
    - UKCTOCS Ca125= 1:9.1
    - UKCTOCS US = 1:12.0
    - PLCO = 1:5.9

Risks of screening

- Anxiety/stress
- Surgical risk
- Anaesthetic risk
- Recovery
- $
- Surgical menopause

CASE 1:

3 years in denial

IOTA - ADNEX model

1. Age of the patient at examination (years) `62`
2. Oncology center (referral center for gyn-oncol)? `no ▾`
3. Maximal diameter of the lesion (mm) `340`
4. Maximal diameter of the largest solid part (mm) `0`
5. More than 10 locules? `no ▾`
6. Number of papillations (papillary projections) `none ▾`
7. Acoustic shadows present? `no ▾`
8. Ascites (fluid outside pelvis) present? `no ▾`
9. Serum CA-125 (U/ml) `14`

`calculate` `Clear`

CASE 2:

The breathatarian

IOTA - ADNEX model

1. Age of the patient at examination (years) 58
2. Oncology center (referral center for gyn-oncol)? no
3. Maximal diameter of the lesion (mm) 290
4. Maximal diameter of the largest solid part (mm) 0
5. More than 10 locules? no
6. Number of papillations (papillary projections) none
7. Acoustic shadows present? no
8. Ascites (fluid outside pelvis) present? no
9. Serum CA-125 (U/ml) 18

calculate   Clear

Additional information is given when moving the mouse pointer over the variable names.

Results

Legend:
- chance of benign tumor
- risk metastatic cancer to the adnexa
- risk stage II–IV ovarian cancer
- risk stage I ovarian cancer
- risk borderline

	Patient Specific Risk	Relative Risk	Baseline Risk

Chart values:
- CHANCE OF BENIGN TUMOR: 93.5
- RISK OF MALIGNANCY: 6.5
- borderline: 2.1
- stage I: 3.4
- stage II - IV: 0.5
- metastatic: 0.5

CASE 3:

The anaesthetic bay

IOTA - ADNEX model

1. Age of the patient at examination (years) `86`
2. Oncology center (referral center for gyn-oncol)? `no ▾`
3. Maximal diameter of the lesion (mm) `35`
4. Maximal diameter of the largest solid part (mm) `12`
5. More than 10 locules? `no ▾`
6. Number of papillations (papillary projections) `none ▾`
7. Acoustic shadows present? `no ▾`
8. Ascites (fluid outside pelvis) present? `no ▾`
9. Serum CA-125 (U/ml) `28`

`calculate` `Clear`

Additional information is given when moving the mouse pointer over the variable names.

Results

Legend:
- chance of benign tum
- risk metastatic cancer
- risk stage II–IV ovaria
- risk stage I ovarian ca
- risk borderline

| CHANCE OF BENIGN TUMOR	RISK OF MALIGNANCY	borderline	stage I	stage II - IV	metastatic
75.6	24.4	3.7	4.8	13.3	2.6

CASE 4:

The traveller

IOTA - ADNEX model

1. Age of the patient at examination (years) `62`
2. Oncology center (referral center for gyn-oncol)? `no ▾`
3. Maximal diameter of the lesion (mm) `28`
4. Maximal diameter of the largest solid part (mm) `08`
5. More than 10 locules? `no ▾`
6. Number of papillations (papillary projections) `none ▾`
7. Acoustic shadows present? `no ▾`
8. Ascites (fluid outside pelvis) present? `no ▾`
9. Serum CA-125 (U/ml) `14`

`calculate` `Clear`

Additional information is given when moving the mouse pointer over the variable names.

Results

- ■ chance of benign tu...
- ■ risk metastatic cance...
- ■ risk stage II–IV ovari...
- ■ risk stage I ovarian c...
- ■ risk borderline

	CHANCE OF BENIGN TUMOR	RISK OF MALIGNANCY	borderline	stage I	stage II - IV	metastatic
%	93.6	6.4	2.7	1.7	1.3	0.7

	Patient Specific Risk	Relative Risk	Baseline Risk